News & Updates

Show Multimedia Only

Do alpha-1 receptor blockers help prevent COVID-19 hospitalization?

22 Oct 2023

Frequent use of alpha-1 receptor blockers is neither harmful nor protective against the risk of uncomplicated or severe COVID-19 hospitalization, a study has shown.

Do alpha-1 receptor blockers help prevent COVID-19 hospitalization?

22 Oct 2023

Face mask use tied to cardiovascular symptoms

20 Oct 2023 by

Use of face masks remains an effective method in preventing COVID-19 transmission, but a recent study in Singapore has found that wearing of face masks is also associated with more self-reported cardiovascular symptoms.

Face mask use tied to cardiovascular symptoms

20 Oct 2023

Ceftazidime-avibactam safe, effective in babies with bacterial infections

20 Oct 2023 by

Treatment with single or multiple doses of ceftazidime-avibactam (CAZ-AVI) results in favourable clinical outcomes and is well tolerated in hospitalized neonates and young infants with suspected or confirmed bacterial infections, according to a phase IIa study presented at IDWeek 2023.

Ceftazidime-avibactam safe, effective in babies with bacterial infections

20 Oct 2023

Beta strain-containing bivalent vaccine protects against various SARS-CoV-2 variants

20 Oct 2023 by

A Beta variant-containing vaccine conferred protection against different SARS-CoV-2 variants, with an acceptable safety profile in adults <60 years, a phase III trial has shown.

Beta strain-containing bivalent vaccine protects against various SARS-CoV-2 variants

20 Oct 2023

Bivalent mRNA vaccine confers protection against SARS-COV-2 infection in young children

18 Oct 2023 by

Bivalent COVID-19 vaccine conferred protection against SARS-COV-2 infection among children and adolescents aged 5–11 years, according to a recent study presented at IDWeek 2023.

Bivalent mRNA vaccine confers protection against SARS-COV-2 infection in young children

18 Oct 2023

Chikungunya vaccine induces robust immune response in adolescents, adults

17 Oct 2023 by

The use of chikungunya virus-like particle vaccine (CHIKV VLP) results in significantly higher seroresponse rate* and superior immunogenicity in adolescents and adults compared with placebo, according to two pivotal phase III trials presented at IDWeek 2023.

Chikungunya vaccine induces robust immune response in adolescents, adults

17 Oct 2023

HIV treatment discontinuation less frequent with B/F/TAF than DTG/3TC

16 Oct 2023 by

In a real-world cohort, virologically suppressed HIV patients who switched from a prior regimen to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) were less likely to discontinue their regimen than those who switched to dolutegravir/lamivudine (DTG/3TC).

HIV treatment discontinuation less frequent with B/F/TAF than DTG/3TC

16 Oct 2023

RSV vaccine effective across two seasons

16 Oct 2023 by

The respiratory syncytial virus (RSV) vaccine by GSK demonstrated sustained effectiveness of about 67 percent among adults 60 years or older across two full RSV seasons in a phase III study, says an infectious disease expert who reported findings at IDWeek 2023.